[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer.
  • Patients with T1 tumour are usually treated with radical local excision, if the lesion is unifocal and the remainder of the vulva is normal.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


2. Potempal AJ, Potempa DM, Görlich HD, Stolpmann RM: [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)]. Arzneimittelforschung; 2007;57(6):299-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
  • [Transliterated title] Intraurethral zu applizierendes Alprostadil zur Behandlung der primär organisch bedingten Erektilen Dysfunktion in der Praxis.
  • In a multicenter clinical monitoring study (observation of use investigation according to 67.6 of the German Drug Law), which was conducted between 2003 and 2005 in 105 urological practices in 314 patients with organic erectile dysfunction (ED), efficacy, safety, convenience and acceptance of intraurethral administered alprostadil (CAS 745-65-3; MUSE - Medicated Urethral System for Erection) was studied.
  • The time of ED was from 2 to 120 months with a mean duration of 21.5 +/- 22 months (median+/-SD.
  • Genesis of the ED was in 55 % of the patients a local damage, which followed in 42.8 % a prostate cancer surgery.
  • In 51.3% of the patients drugs, which were known to induce ED, were suspected to have caused or partially caused the impairment.
  • Alprostadil (MUSE) was applicated three times in doses of 250, 500 or 1000 microg.
  • In patients after surgery because of prostate cancer very good and good efficacy improved in comparison to the first application about 20% and concerned 53.9 % of the patients after the third application.
  • 81.1% intended to continue the treatment.
  • In a retrospective comparison with other drugs for the treatment of ED intracavernosal alprostadil ("SKAT") was slightly more effective than intraurethral alprostadil (MUSE) (32.1% vs 25 %), but alprostadil (MUSE) was assessed more useful by 82.1% and preferred by 78.6% of the patients.
  • Five adverse events were reported (slight urethral pain).
  • In this non-interventional investigation the good efficacy and tolerability of intraurethral applicated alprostadil (MUSE) as a second-line therapy after failure or minor efficacy of PDE-5 inhibitors and other oral drugs was comparable with the results of the clinical trials.
  • [MeSH-major] Alprostadil / therapeutic use. Erectile Dysfunction / drug therapy. Vasodilator Agents / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Apomorphine / therapeutic use. Body Mass Index. Dopamine Agonists / therapeutic use. Double-Blind Method. Drug Therapy, Combination. Humans. Injections. Male. Middle Aged. Orgasm / drug effects. Penile Erection / drug effects. Phosphodiesterase Inhibitors / therapeutic use. Postoperative Complications / drug therapy. Quality of Life. Urethra

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • Hazardous Substances Data Bank. APOMORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688074.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Phosphodiesterase Inhibitors; 0 / Vasodilator Agents; F5TD010360 / Alprostadil; N21FAR7B4S / Apomorphine
  •  go-up   go-down


3. Huang Z, Chen Q, Trncic N, LaRue SM, Brun PH, Wilson BC, Shapiro H, Hetzel FW: Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation. Radiat Res; 2004 Jun;161(6):723-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
  • The aim of this study was to evaluate the effects of photodynamic therapy (PDT) using a novel palladium bacteriopherophorbide photosensitizer TOOKAD (WST09) on canine prostate that had been pretreated with ionizing radiation.
  • To produce a physiological and anatomical environment in canine prostate similar to that in patients for whom radiotherapy has failed, canine prostates (n = 4) were exposed to ionizing radiation (54 Gy) 5 to 6 months prior to interstitial TOOKAD-mediated PDT.
  • Interstitial measurements of tissue oxygen profile (pO(2)) and of local light fluence rate were also measured.
  • There was no noticeable damage to the urethra, bladder or adjacent colon.
  • The preliminary results obtained from a small number of animals indicate that TOOKAD-PDT can effectively ablate prostate pretreated with ionizing radiation, and so it may provide an alternative modality for those prostate cancer patients for whom radiotherapy has failed.

  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Apr;30(4):341-8 [9147082.001]
  • [Cites] Br J Urol. 1997 Dec;80(6):898-902 [9439405.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):555-62 [8759616.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S256-9 [8763892.001]
  • [Cites] J Urol. 1996 Jul;156(1):258-60 [8648818.001]
  • [Cites] Med Phys. 1994 Jul;21(7):1149-56 [7968848.001]
  • [Cites] N Engl J Med. 1994 Oct 13;331(15):996-1004 [7880240.001]
  • [Cites] J Urol. 1994 May;151(5):1411-5 [8158797.001]
  • [Cites] Eur Urol. 1991;20(3):211-9 [1726638.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Photochem Photobiol. 2003 Nov;78(5):496-502 [14653582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):384-90 [12957249.001]
  • [Cites] Photochem Photobiol. 2003 Jan;77(1):81-8 [12856887.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):782-9 [12640688.001]
  • [Cites] Urol Oncol. 2002 May-Jun;7(3):125-32 [12474546.001]
  • [Cites] Mol Cell Endocrinol. 2002 Nov 29;197(1-2):251-5 [12431819.001]
  • [Cites] Photochem Photobiol. 2002 Oct;76(4):438-45 [12405153.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1427-32 [12352410.001]
  • [Cites] Photochem Photobiol. 2002 Aug;76(2):197-203 [12194217.001]
  • [Cites] Cancer Control. 2001 Nov-Dec;8(6):522-31 [11807422.001]
  • [Cites] Eur Urol. 2001 Aug;40(2):124-9 [11528187.001]
  • [Cites] J Urol. 2001 May;165(5):1795-801 [11342978.001]
  • [Cites] J Endourol. 2001 May;15(4):437-40; discussion 447-8 [11394458.001]
  • [Cites] Prostate. 1997 Jul 1;32(2):89-98 [9215396.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3A):1467-70 [9179185.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):651-60 [11297261.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):737-42 [11251168.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1021-31 [10478661.001]
  • [Cites] Urology. 1999 Jan;53(1):11-8 [9886581.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5425-31 [9850075.001]
  • [Cites] J Clin Laser Med Surg. 1998 Feb;16(1):9-12 [9728124.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):323-8 [9612199.001]
  • [Cites] Radiat Res. 1997 Jan;147(1):86-91 [8989374.001]
  • (PMID = 15161347.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA043892; United States / NCI NIH HHS / CA / CA 43892; United States / NCI NIH HHS / CA / P01 CA043892-14A20010
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / Photosensitizing Agents; 0 / palladium-bacteriopheophorbide; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS4337; NLM/ PMC1237001
  •  go-up   go-down


Advertisement
4. Tsukamoto T, Yonese J, Kin T, Samejima T, Hasegawa Y, Fukui I, Ishikawa Y: [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment]. Nihon Hinyokika Gakkai Zasshi; 2002 Mar;93(3):483-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment].
  • Laser treatment is considered to be effective in treating carcinoma in situ of the penis.
  • We, however, report a case with carcinoma in situ of the penis which developed invasive carcinoma and inguinal lymphnode metastases only 6 months after the laser treatment.
  • A physical examination revealed thick erythema, 12 millimeters in diameter, around the external urethral meatus.
  • Although the lesion appeared to slightly extend into the urethra, it was primarily treated with the CO2 laser.
  • Six months after the treatment, however, local recurrence was confirmed by the touch smear cytology, resulting in the partial amputation of the penis.
  • The histopathological examination revealed subepithelial and marked lymphatic invasion of the tumor and positive margin in the urethral stump (squamous cell carcinoma in situ).
  • The patient received adjuvant chemotherapy and has been alive and well without evidence of disease 40 months after the initial treatment.
  • [MeSH-minor] Aged. Disease Progression. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968805.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol; 2003 Aug;17(4):663-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and regional recurrence of vulval cancer: management dilemmas.
  • Vulval cancer has an incidence of 1-2/100000.
  • Approximately one-third of patients develop recurrent disease usually within the first 2 years following primary treatment.
  • Isolated vulval recurrences account for up to 50% of all cases and these recurrences are often amenable to curative surgery with radical wide local excision.
  • Radical exenterative procedures are considered when the recurrence involves the urethra, bladder, vagina and/or the anorectal canal.
  • Chemoradiation therapy may be used pre-operatively or to palliate the disease.
  • Surgical effort to debulk large-volume groin disease is often unsuccessful and chemoradiation therapy is the cornerstone of treatment.
  • The management of retroperitoneal and distant disease recurrence is generally based on symptom control as radiation therapy and chemotherapy have limited success.
  • Palliative medicine should be integrated early in the management plan both in patients with incurable recurrent disease and in those undergoing potentially curative treatments.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Palliative Care / methods. Vulvar Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hemorrhage / therapy. Humans. Inguinal Canal. Neoadjuvant Therapy. Pelvis. Radiotherapy, Adjuvant. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12965138.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


6. Dalbagni G, Donat SM, Eschwège P, Herr HW, Zelefsky MJ: Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol; 2001 Nov;166(5):1759-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra.
  • PURPOSE: We evaluated a multimodality approach to locally advanced urethral carcinoma in women.
  • MATERIALS AND METHODS: Between August 1996 and July 1999, 6 women were treated for locally advanced carcinoma of the urethra with anterior pelvic exenteration followed by high dose 192iridium intraoperative radiation therapy.
  • Four of the 6 patients were also treated with neoadjuvant or concomitant platinum based chemotherapy.
  • RESULTS: Two patients had no evidence of disease, 3 had distant metastasis and 2 had local recurrence at a mean followup of 21 months (range 12 to 47).
  • Local control seems to have improved.
  • We must evaluate a larger cohort of patients to determine this impact of the combined modality on local control and patient survival.
  • [MeSH-major] Brachytherapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Pelvic Exenteration. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11586218.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • MEASUREMENTS: Cancer-specific survival (CSS) and overall survival (OS) probability for asymptomatic and symptomatic recurrent patients were estimated using the Kaplan-Meier method.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors


8. Pieras E, Palou J, Salvador J, Rosales A, Marcuello E, Villavicencio H: Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol; 2003 Aug;44(2):222-5; discussoion 225
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
  • PURPOSE: To assess the bladder preservation rate and cancer-specific survival after conservative treatment of superficial relapses in invasive tumors after bladder preservation.
  • MATERIAL AND METHODS: Fifty-one patients with invasive bladder tumor (T2) were treated using transurethral resection (TUR) followed by three cycles of systemic chemotherapy (carboplatin-vinblastine).
  • After three weeks, an endoscopic reappraisal was made including deep TUR of the site of the original tumor and multiple cold cup biopsies.
  • RESULTS: With a median follow-up of 63 months, 18 patients recurred as superficial TCC tumor (43%).
  • With a median follow-up of 44 months after TUR of first superficial relapse, there was only one case with progression of the disease without any evidence of bladder tumor.
  • Eighty-three percent of the patients who had superficial recurrence retained their bladders, with 94% cancer-specific survival.
  • Cis is the most frequent type of superficial recurrence.
  • Superficial recurrences do not imply a worse prognosis for bladder preservation or cancer-specific survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Neoplasm Recurrence, Local / diagnosis. Transurethral Resection of Prostate. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] BCG Vaccine / administration & dosage. Carboplatin / administration & dosage. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Combined Modality Therapy. Cystectomy. Disease Progression. Follow-Up Studies. Humans. Lymphatic Metastasis. Muscle, Smooth / pathology. Neoplasm Staging. Outcome and Process Assessment (Health Care). Prognosis. Survival Analysis. Urethra / surgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12875942.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BCG Vaccine; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


9. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA: Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol; 2005 Jun;173(6):1958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
  • We describe our experience with 10 patients with penile or urethral involvement.
  • RESULTS: Of 10 patients with penile or urethral melanoma 1997 American Joint Committee on Cancer melanoma pathological stage was T1 (depth less than 0.75 mm) in 4, T2 (0.75 to 1.5 mm) in 3 and T3 (1.51 to 4 mm) in 3.
  • In 7 patients with T1-2N0M0 disease there were no local recurrences after wide local excision (WLE) or partial penectomy at a median followup of 35 months.
  • One patient died of melanoma that developed at a second primary site.
  • Six patients with scrotal melanoma were treated with WLE without local recurrences.
  • Three of the 6 patients had palpable inguinal nodes, of whom 2 died after chemotherapy for unresectable disease and 1 died of other causes 51 months after negative BILND.
  • The 3 men with clinically negative groins who did not undergo prophylactic BILND had distant (1) or regional (2) metastases and died of disease.
  • CONCLUSIONS: Partial penectomy or WLE provided effective local control for low stage penile or urethral melanomas and all scrotal lesions.
  • Patients showing clinically positive, proven metastasis died despite appropriate surgical procedures and multi-agent chemotherapy.
  • Prophylactic modified inguinal lymphadenectomy should be considered in select patients with penile, scrotal and anterior urethral melanoma.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Melanoma / surgery. Penile Neoplasms / surgery. Scrotum / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Apr;175(4):1574-5; author reply 1575-6 [16516049.001]
  • (PMID = 15879790.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Startsev V, Pouline I: Adjuvant therapy in different risk-groups of patients with superficial bladder cancer. Arch Ital Urol Androl; 2005 Jun;77(2):93-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in different risk-groups of patients with superficial bladder cancer.
  • OBJECTIVES: We assessed and compared the outcomes of two different courses of adjuvant therapy to patients with superficial bladder TCC.
  • METHODS: The study included 142 patients (28 women and 114 men with a median age of 58.5 years) with newly diagnosed bladder transitional cell carcinoma (TCC), who underwent transurethral resection of bladder tumor (TURBT) between October 2002 and October 2003.
  • The main criteria for adjuvant treatment were: grade, number and location of the tumor in the bladder The group of patients (group A) with G3 and multicentric lesions, localized at the lower third of the bladder, underwent BCG-therapy according the conventional schedule (60 patients, 42.3%).
  • In group B (82 patients, 57.7%) patients underwent local chemotherapy (Thiotepa 80 mg p/week or Doxorubicin 50 mg p/week), started within 24 hours after operation.
  • A second-look TURBT was performed within 6 weeks of treatment course in both groups.
  • Adjuvant therapy was continued in all patients, except four patients with G3 and two patients with T2 stage who underwent more aggressive treatment (4 cystectomies and 2 external beam radiotherapy).
  • We switched 16 patients in group B with recurrent cancer to BCG treatment.
  • Nobody of TURP-operated patients had recurrence in the distal part of urethra, and toxicity level of TURP-operated patients was not worse than in the whole patients cohort (not more than grade II).
  • CONCLUSION: BCG adjuvant therapy demonstrated good results in the treatment of the recurrence of superficial TCC.
  • However, in patients with low recurrence risk we used chemotherapy successfully.
  • Patients with T1G3 tumors, being at high risk of residual, or even invasive, cancer, could be offered definitive therapy within a 1-year period.
  • Patients who underwent simultaneous TURP for relief of LUTS did not show cancer recurrences in the operated area or an higher toxicity of adjuvant treatment.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146269.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / BCG Vaccine; 80168379AG / Doxorubicin; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


11. Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BC, Scherz A, Salomon Y, Hetzel FW: Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol; 2002 Oct;76(4):438-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
  • Photodynamic therapy (PDT) uses light to activate a photosensitizer to achieve localized tumor control.
  • In this study, PDT mediated by a second-generation photosensitizer, palladium-bacteriopheophorbide WST09 (Tookad) was investigated as an alternative therapy for prostate cancer.
  • PDT was performed by irradiating the surgically exposed prostate superficially or interstitially at 763 nm to different total fluences (100 or 200 J/cm2; 50, 100 or 200 J/cm) at 5 or 15 min after intravenous administration of the drug (2 mg/kg).
  • The local light fluence rate and temperature were monitored by interstitial probes in the prostate.
  • All animals recovered well, without urethral complications.
  • During the 1 week to 3 month post-treatment period, the prostates were harvested for histopathological examination.
  • The PDT-induced lesions showed uniform hemorrhagic necrosis and atrophy, were well delineated from the adjacent normal tissue and increased linearly in diameter with the logarithm of the delivered light fluence.
  • A maximum PDT-induced lesion size of over 3 cm diameter could be achieved with a single interstitial treatment.
  • At therapeutic PDT levels, there was no structural or functional urethral damage even when the urethra was within the treated region.
  • Hence, Tookad-PDT appears to be a promising candidate for prostate ablation in patients with recurrent, or possibly even primary, prostate cancer.
  • [MeSH-major] Bacteriochlorophylls / pharmacology. Photochemotherapy. Photosensitizing Agents / pharmacology. Prostate / drug effects. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12405153.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA43892
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / Photosensitizing Agents; 0 / palladium-bacteriopheophorbide
  •  go-up   go-down


12. Salom EM, Penalver M: Recurrent vulvar cancer. Curr Treat Options Oncol; 2002 Apr;3(2):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent vulvar cancer.
  • Recurrent vulvar cancer occurs in an average of 24% of cases after primary treatment after surgery with or without radiation.
  • The relatively few primary vulvar cancers, combined with the low proportion of recurrences, has made it difficult to perform randomized studies to document the most appropriate therapeutic modalities.
  • Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery.
  • Recently, radiation and chemotherapy have been combined with very encouraging results.
  • The therapeutic modality used depends on the location and extent of the recurrence.
  • Lateralized local vulvar recurrences treated with a wide radical local excision with inguinal lymphadectomy results in an excellent cure rate of 70%.
  • With a central pelvic recurrence with antecedent radiotherapy involving the urethra, upper vagina, and rectum, total pelvic exenteration is indicated in a select group of patients with curative intent.
  • Radiotherapy or chemoradiation concomitantly with wide radical local excision of an advanced vulvar has proven successful in avoiding an exenteration, with improved survival and less morbidity.
  • Prospective and retrospective studies have shown excellent results using radiation or chemoradiation with wide radical local excision in patients with locally advanced disease in whom adequate resection margins are difficult to achieve (with a central lesion requiring exenteration) or with debilitating medical conditions that preclude surgery.
  • In these patients, chemoradiation has shown favorable results when used before a wide local resection.
  • In patients with advanced local disease, external beam and interstitial radiation has been used for palliative and curative intent with encouraging results.
  • Regional recurrences to the inguinal and pelvic lymph nodes have been shown to have a poor prognosis with a high mortality rate.
  • We recommend that inguinal recurrences without prior radiation therapy undergo excision followed by radiotherapy with chemosensitization.
  • With pelvic recurrences, we recommended chemoradiation as the treatment modality.
  • In the subset of patients with distant metastasis, chemotherapy may be offered; however, few studies have been performed to advocate any single combination.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1990 Sep;163(3):1007-15 [2403127.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1943-9 [6478428.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):91-8 [10411801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1193-7 [10725631.001]
  • [Cites] Am J Obstet Gynecol. 1990 May;162(5):1278-82 [2339729.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):202-5 [7622106.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):263-7 [2504651.001]
  • [Cites] Acta Radiol Oncol. 1984;23(5):345-8 [6095605.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1383-9 [1442996.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):189-95 [8428690.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(4):318-22 [8344328.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):343-8 [9731836.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1001-5 [2342725.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2835-8 [1451064.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Gynecol Oncol. 1986 Feb;23(2):192-8 [3943761.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):309-14 [2227541.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26 [3549645.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jun 1;143(3):340-51 [7081350.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Am J Clin Oncol. 1987 Apr;10(2):171-81 [3565317.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):14-20 [1427394.001]
  • (PMID = 12057077.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


13. Cresswell J, Roberts JT, Neal DE: Urethral recurrence after radical radiotherapy for bladder cancer. J Urol; 2001 Apr;165(4):1135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral recurrence after radical radiotherapy for bladder cancer.
  • PURPOSE: Following cystectomy for bladder cancer, orthotopic reconstruction may result in a decreased risk of urethral recurrence compared to cutaneous diversion.
  • We evaluate the rate of urethral recurrence after radical external beam radiotherapy.
  • Patients treated with chemotherapy were excluded from study.
  • Tumor stages were T1 in 7%, T2 in 41%, T3 in 42% and T4a in 10% of the patients.
  • Urethral recurrence developed in 7 (3.2%) cases and was detected within 18 months (median 10 months, range 3 months to 5 years) of followup in 5.
  • In 2 of these 7 cases recurrence developed in the prostatic urethra, and when these 2 cases were excluded from analysis the recurrence rate decreased to 2.3%.
  • A total of 64 men completed 5-year followup, with a 4.7% rate of urethral recurrence (3.1% excluding prostatic urethral recurrence).
  • Multifocal disease, bladder neck involvement, prostatic disease and cis were possible risk factors for urethral recurrence.
  • CONCLUSIONS: The risk of urethral recurrence after radical radiotherapy for transitional cell carcinoma of the bladder is comparable with that reported after orthotopic reconstruction.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Urethral Neoplasms / prevention & control. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystectomy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Urinary Diversion


14. Huguet J, Gaya JM, Sabaté S, Palou J, Villavicencio H: [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. Actas Urol Esp; 2010 Jan;34(1):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
  • [Transliterated title] Cistectomía radical en tumores vesicales no músculoinfiltrantes que fracasan al tratamiento con bacilo de Calmette-Guérin.
  • OBJECTIVE: To assess the characteristics and outcomes of patients with non-muscle invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC) due to BCG failure.
  • MATERIALS AND METHODS: Ninety-five (11%) of the 864 patients undergoing radical cystectomy (RC) at our center from 1989 to 2002 had received prior treatment with BCG.
  • Of these, 62 (65.2%) underwent RC due to relapsing, high-risk NMIBC or CIS despite BCG therapy.
  • A stage >or= pT2 tumor was reported in the cystectomy specimen in 17 (27%) of these patients, who were considered to have been understaged.
  • Median time from tumor diagnosis to tumor progression was 24 months (10th-90th percentile, 6-98 months).
  • CONCLUSION: In patients with high-risk NMIBCs who fail BCG therapy, RC should be performed before progression because survival is decreased when the RC specimen shows muscle-invasive disease.
  • [MeSH-minor] Aged. BCG Vaccine / therapeutic use. Biopsy. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome. Urethra / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223134.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


15. Rinaldi M, Cormio G, Bucaria V, Di Tonno P, Marino F, Altomare DF: [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma]. Suppl Tumori; 2005 May-Jun;4(3):S208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction with skin flaps of the posterior aspect of the thighs after total pelvic evisceration with removal of vulvo-perineal soft tissues in recurrent vulvar squamous carcinoma].
  • We report of a case of a fortythree years old women affected by squamous cell cancer of the vulva (T3N0M0).
  • Despite curative treatment (radical vulvectomy with bilateral inguinal and femoral lymphadenectomy), after 41 months she had a local recurrence, retreated with surgery and radiotherapy; another recurrence, after 29 months was treated with chemotherapy, without results.
  • Because of local diffusion with infiltration of the urethra and anus, the patient was submitted to demolitive operation (total pelvic evisceratio, excision of pelvic and perineal soft tissues and reconstruction with rotating skin flaps of the posterior face of the thighs).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Perineum. Reconstructive Surgical Procedures / methods. Soft Tissue Neoplasms / surgery. Surgical Flaps. Thigh / surgery. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437992.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL: Management of urethral recurrence after orthotopic urinary diversion. BJU Int; 2010 Jul;106(1):56-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of urethral recurrence after orthotopic urinary diversion.
  • STUDY TYPE: Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder.
  • Six patients (2.3%) developed local recurrence of urothelial cancer (UC) within the urethra after this treatment.
  • The median (range) time to presentation with recurrence after RC was 2.4 (0.7-3.6) years for pT1-4 UC.
  • Recurrences were treated with various methods, including transurethral resection, urethrectomy with conversion of neobladder to continent catheterizable diversion, and chemotherapy.
  • CONCLUSIONS: In our experience, local recurrences involving the urethra are infrequent.
  • Neoadjuvant chemotherapy should be considered for recurrences with adverse clinicopathological features.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Neoplasm Recurrence, Local / surgery. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Treatment Outcome. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002676.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


17. Liptak JM, Brutscher SP, Monnet E, Dernell WS, Twedt DC, Kazmierski KJ, Walter CU, Mullins MN, Larue SM, Withrow SJ: Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs. Vet Surg; 2004 Sep-Oct;33(5):505-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs.
  • OBJECTIVE: To assess cystoscopic transurethral resection (TUR) for the palliative management of dogs with neoplastic infiltration of the urethra.
  • METHODS: Cystoscopic examination and electrosurgical TUR were performed in dogs with urination difficulties caused by prostatic or urethral neoplasia.
  • Cystoscopic examination was used to determine the extent of neoplastic involvement of the urethra.
  • TUR involved piecemeal removal of neoplastic tissue from the urethral lumen using an electrocautery cutting loop.
  • In 2 male dogs, intraoperative radiation therapy (IORT) was used to treat both prostatic neoplasia and the sublumbar lymph node bed.
  • Surgical technique, complications, adjuvant treatment, and outcome were recorded.
  • RESULTS: TUR was performed in 3 male dogs with prostatic carcinoma and 2 female dogs with urethral transitional cell carcinoma (TCC).
  • Iatrogenic urethral perforation occurred during TUR in 3 dogs.
  • Treatment-related complications included urinary tract infection and tumor seeding.
  • Local tumor progression and metastasis occurred in all dogs.
  • CONCLUSIONS: TUR (in combination with chemotherapy+/-IORT) resulted in rapid palliation of urination difficulties in male dogs with prostatic carcinoma.
  • In female dogs with urethral TCC, however, electrosurgical TUR cannot be recommended because of a high intra- and postoperative complication rate with no improvement in postoperative management compared with historical reports of tube cystostomy.
  • In female dogs with urethral TCC, electrosurgical TUR does not provide any advantages compared with tube cystostomy.
  • [MeSH-major] Carcinoma, Transitional Cell / veterinary. Dog Diseases / surgery. Electrosurgery / veterinary. Prostatic Neoplasms / veterinary. Urethral Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15362989.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Racioppi M, Volpe A, Cappa E, D'Agostino D, Pinto F, D'Addessi A, Sacco E, Bassi P: Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach. Urol Int; 2010;85(3):266-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach.
  • PATIENTS AND METHODS: From September 2007 to November 2009, 40 consecutive evaluable patients with pathologically confirmed intermediate-risk non-muscle-invasive bladder cancer (NMIBC) were enrolled after complete transurethral resection of all visible tumors.
  • 40 mg MMC diluted in 50 ml of saline was instilled in the bladder three times a week for 2 weeks.
  • RESULTS: All patients fulfilled the scheduled treatment.
  • The local adverse events seen were negligible, while no significant deviation from normal values was observed in blood counts for each patient.
  • CONCLUSION: MMC is a well-known chemotherapeutic agent for the intravesical therapy of NMIBC.
  • No significant local or systemic toxicity was reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mitomycin / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Time Factors. Treatment Outcome. Urethra / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20516670.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


19. Bissada NK, Yakout HH, Fahmy WE, Gayed MS, Touijer AK, Greene GF, Hanash KA: Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma. J Urol; 2003 Feb;169(2):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Penile squamous cell carcinoma subsequently invades local structures, corpora cavernosa and the urethra, and metastasizes to the inguinal lymph nodes.
  • We studied the effect of primary tumor resections tailored to the anatomical extent of the cancer with preservation of uninvolved structures in select patients with invasive penile squamous cell carcinoma.
  • Patient age, tumor extent and grade, operative details, outcome and length of followup were analyzed.
  • RESULTS: Tumor size ranged from 1.5 to 8 cm. in diameter.
  • Chemotherapy was given to 7 patients with extensive inguinal lymphadenopathy and to 2 of 5 with pathologically positive lymph nodes.
  • Tumor resection with no sacrifice of function was performed in 2 patients in whom 3 small recurrences developed.
  • Of the 7 patients with advanced lymphadenopathy 5 and of 5 patients with pathologically positive lymph nodes at presentation 1 died of the cancer but had no local recurrence in the penis.
  • CONCLUSIONS: In a minority of patients with anatomically suitable penile cancer conservative surgical techniques are safe and provide equal tumor control compared to conventional resections.
  • The anatomical situation and tumor characteristics should dictate the choice of treatment for the primary penile lesion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544296.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F: Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol; 2010 Aug;58(2):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND PARTICIPANTS: Two hundred ten newly diagnosed T1 bladder cancer patients were prospectively randomised to two groups between January 2001 and January 2005.
  • All patients (groups 1 and 2) received the first instillation of intravesical chemotherapy within 24h after the initial resection.
  • Urine cytology and follow-up cystoscopy were performed at 3-mo intervals for the first year, biannually for the second year, and annually thereafter.
  • All patients were followed until death or a minimum of 54 mo.
  • RESULTS AND LIMITATIONS: The mean follow-up period was 66.1 mo without a significant difference between the groups.
  • Median recurrence-free survival was 47 mo for group 1 compared with 12 mo for group 2.
  • Median progress-free survival was 73 mo for group 1 compared to 53.5 mo for group 2.
  • Only 5 of the 30 patients in group 1 died of cancer compared to 11 of the 35 patients in group 2 (p=0.038).
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Neoplasm Recurrence, Local / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystectomy / methods. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Reoperation. Survival Rate. Time Factors. Treatment Outcome. Urethra


21. Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S: A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol; 2004 Jan;171(1):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
  • PURPOSE: In a prospective randomized controlled study, we investigated the optimal schedule for intravesical instillation of epirubicin for maximizing its effect on prophylaxis and disease progression after transurethral resection of newly diagnosed Ta/T1 bladder cancer.
  • MATERIALS AND METHODS: The patients were instilled with epirubicin (30 mg/30 ml in normal saline) within 24 hours after transurethral resection and then randomized into 2 groups after a definite histopathological diagnosis of Ta/T1 bladder cancer.
  • CONCLUSIONS: Our study indicates that long-term instillation of epirubicin is more effective than short-term instillation in preventing recurrence after transurethral resection of Ta/T1 bladder cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Transitional Cell / prevention & control. Epirubicin / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / prevention & control
  • [MeSH-minor] Administration, Intravesical. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prospective Studies. Time Factors. Urethra

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14665865.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


22. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution experience with primary tumours of the male urethra.
  • OBJECTIVE: To assess primary tumours of the urethra in males.
  • PATIENTS AND METHODS: We retrospectively reviewed our database from 1986 to 2006 for primary tumours of the male urethra; nine patients with primary tumours of the urethra were analysed and follow-up information was obtained.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • CONCLUSION: Primary carcinoma of the male urethra is a rare entity.
  • Local surgical tumour control is essential for long-term survival, but the extent of surgery depends on tumour location and stage.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation.
  • Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed.
  • Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered.
  • After chemotherapy, CT showed complete response (CR) of all lymph nodes.
  • Local control in the bladder was considered to be good, so total prostatectomy and retroperitoneal lymph node dissection was selected instead of total cystoprostatectomy.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / secondary. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Prostatectomy. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Riesz P, Székely E, Törzsök P, Majoros A, Szendroi A, Dombovári P, Romics I: [Can inverted papilloma in urinary bladder be considered as a benign tumor]. Orv Hetil; 2010 Jan 17;151(3):92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can inverted papilloma in urinary bladder be considered as a benign tumor].
  • According to literature data, this disease is not malignant, and has low recurrence rate.
  • They aimed to find out the rate of inverted papilloma recurrences, and transformations into malignant bladder cancer.
  • In one case, inverted papilloma and transitiocellular tumor (pTa G1) were detected.
  • In one patient, inverted papilloma was found by control cystoscopy after transurethral resection of bladder (pT1 G2) and local chemotherapy 15 months later.
  • CONCLUSIONS: Based on authors' experience, inverted papilloma of the urinary bladder is a benign lesion, but malignant changes or concomitant transitiocellular tumor may occur, thus follow-up is needed.
  • Although references are not standardized, authors suggest following patients with inverted papilloma as a primary (pTa G1) bladder cancer.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Papilloma, Inverted / pathology. Papilloma, Inverted / surgery. Precancerous Conditions / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Urethra

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061266.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down






Advertisement